CDMO Samsung Biologics’ $897 Million Pfizer Partnership Signals the Potential of Newly Constructed Plant 4
Samsung Biologics, a contract development and manufacturing organization (CDMO), recently added to its industry-leading biomanufacturing capacity with the completion of its fourth plant. Plant 4, which became fully operational in June, adds 240,000 liters of